MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12902-025-01872-w

Медицинская библиотека · BMC endocrine disorders · 2025

Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data.

Okamoto Aki, Yokokawa Hirohide, Nagamine Tomoko, Goto Kento, Fukuda Hiroshi, Hisaoka Teruhiko, Naito Toshio

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Fibrates are suitable for the treatment of patients with high triglyceride (TG) levels. Although pemafibrate (PEMA) has been reported to have beneficial and pleiotropic actions, clinical examinations of the efficacy of PEMA for Japanese patients with hypertriglyceridemia are still limited in actual clinical settings. The aim was to evaluate the efficacy of PEMA by analyzing data from diabetic patients treated with PEMA in clinical practice.

METHODS

Patients with type 2 diabetes mellitus and hypertriglyceridemia who were started on PEMA for at least 3 months were included in the analysis. Changes in lipid metabolism, liver function, renal function, and blood tests from before to after 3 months of PEMA treatment were evaluated.

RESULTS

A total of 100 eligible patients were included in the analysis (72 males, mean age 52.9 years). TG levels decreased significantly, and high-density lipoprotein cholesterol levels increased significantly after 3 months of therapy. Low-density lipoprotein cholesterol levels were not significantly changed. Liver-related parameters showed a significant decrease. In addition, a significant decrease in creatinine levels was found in patients switching from other fibrates. There were no severe adverse events.

CONCLUSION

PEMA showed beneficial effects on lipid metabolism and liver function. The improvement of lipid metabolism was found in patients switching from other fibrates. It is possible that PEMA may improve lipid metabolism in patients with hypertriglyceridemia.

CLINICAL TRIAL NUMBER: Not applicable.

Для цитирования: Okamoto Aki, Yokokawa Hirohide, Nagamine Tomoko, Goto Kento, Fukuda Hiroshi, Hisaoka Teruhiko, Naito Toshio. Effect and safety of pemafibrate for patients with type 2 diabetes mellitus and hypertriglyceridemia: a retrospective analysis of clinical data.. BMC endocrine disorders. 2025. DOI: 10.1186/s12902-025-01872-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.